Diabetes Research and Clinical Practice
Volume 90, Issue 1 , Pages 45-53 , October 2010

Association between the -634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: A meta-analysis

  • Tongfeng Zhao

      Affiliations

    • Department of Geriatrics, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Number 88, Jiefang Road, Hangzhou, Zhejiang 310009, PR China
    • Corresponding Author InformationCorresponding author. Tel.: +86 571 887783690; fax: +86 571 87022660.
    • ,
  • Jiangpei Zhao

      Affiliations

    • Department of Geriatrics, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, PR China

Received 9 March 2010 ,Revised 1 May 2010 ,Accepted 27 May 2010.

References 

  1. Congdom N, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA. 2003;290:2057–2060
  2. Crawford TN, Alfaro DV, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev. 2009;1:8–13
  3. Gomez-Ulla F. Diabetic retinopathy. Curr Diabetes Rev. 2009;1:1–2
  4. Alcolado J. Genetics of diabetic complications. Lancet. 1998;351:230–231
  5. Patel S, Chen H, Tinkham NH, Zhang K. Genetic susceptibility of diabetic retinopathy. Curr Diab Rep. 2008;4:257–262
  6. Balasubramanyam M, Rema M, Premanand C. Biochemical and molecular mechanisms of diabetic retinopathy. Curr Sci. 2002;12:1506–1514
  7. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002;5:1635–1639
  8. Frank RN. Vascular endothelial growth factor-its role in retinal vascular proliferation. N Engl J Med. 1994;331:1519–1520
  9. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs. 2004;10:1275–1293
  10. Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol. 1994;112:1476–1482
  11. Konopatskaya O, Churchill AJ, Harper SJ, Bates DO, Gardiner TA. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis. 2006;12:626–632
  12. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457–10461
  13. Churchill AJ, Carter JG, Ramsden C, Turner SJ, Yeung A, Brenchley PE, et al. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;8:3611–3616
  14. Nakamura S, Iwasaki N, Funatsu H, Kitano S, Iwamoto Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;1:21–26
  15. Petrovic MG, Korosec P, Kosnik M, Osredkar J, Hawlina M, Peterlin B, et al. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis. 2008;14:1382–1387
  16. Uthra S, Raman R, Mukesh BN, Rajkumar SA, Padmaja KR, Paul PG, et al. Association of VEGF gene polymorphisms with diabetic retinopathy in a south Indian cohort. Ophthal Genet. 2008;1:11–15
  17. Suganthalakshmi B, Anand R, Kim R, Mahalakshmi R, Karthikprakash S, Namperumalsamy P, et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis. 2006;12:336–341
  18. Szaflik JP, Wysocki T, Kowalski M, Majsterek I, Borucka AI, Blasiak J, et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;1:39–43
  19. Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrol Dial Transplant. 2007;3:827–832
  20. Kangas-Kontio T, Vavuli S, Kakko SJ, Penna J, Savolainen ER, Savolainen MJ, et al. Polymorphism of the manganese superoxide dismutase gene but not of vascular endothelial growth factor gene is a risk factor for diabetic retinopathy. Br J Ophthalmol. 2009;10:1401–1406
  21. Yong D, QingQing W, Hua L, Yang LX, QingLing Z, Ying H, et al. Association of uteroglobin G38A polymorphism with IgA nephropathy: a meta-analysis. Am J Kidney Dis. 2006;1:1–7
  22. Thakkinstian A, McElduff P, D’Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med. 2005;9:1291–1306
  23. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121–145
  24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simples, graphical test. BMJ. 1997;315:629–634
  25. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KGM. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol. 2006;6:50
  26. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KGM. MIX: comprehensive free software for meta-analysis of causal research data. Version 1.7; 2008 [http://mix-for-meta-analysis.info].
  27. Burgos R, Simo R, Audi L, Mateo C, Mesa J, Garcia-Ramirez M, et al. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia. 1997;40:1107–1109
  28. Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo TK. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445–450
  29. Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2005;139:476–481
  30. Van Eeden PE, Tee LB, Lukehurst S, Lai CM, Rakoczy EP, Beazley LD, et al. Early vascular and neuronal changes in a VEGF transgenic mouse model of retinal neovascularization. Invest Ophthalmol Vis Sci. 2006;10:4638–4645
  31. Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;1:36–47
  32. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;11:1820–1828
  33. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, et al. Vascular endothelial growth factor- induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;9:1473–1480

PII: S0168-8227(10)00278-0

doi: 10.1016/j.diabres.2010.05.029

Diabetes Research and Clinical Practice
Volume 90, Issue 1 , Pages 45-53 , October 2010

Article Tools

* Image Usage & Resolution